A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Cleminorexton Compared With Placebo in Participants With Central Disorders of Hypersomnolence
Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness [EDS]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.
While all conditions result in feeling sleepy, there are some differences in other common symptoms:
- NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.
- NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.
Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable cleminorexton is in NT1 and NT2 and learn about what the drug does to the body. Another goal of the study is to see if cleminorexton can help people with NT1 and NT2 feel less sleepy and make other symptoms better.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The SAPPHIRE Clinical Trial
The Sponsor may in the future, through a protocol amendment, expand the protocol to include participants with idiopathic hypersomnia (IH) in Cohort C.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Centessa Pharmaceuticals
- Telefonnummer: 617-468-5770
- E-mail: ORX750trials@centessa.com
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35213
- Rekruttering
- Birmingham, Alabama
-
-
Colorado
-
Colorado Springs, Colorado, Forenede Stater, 80918
- Rekruttering
- Colorado Springs, Colorado
-
-
Florida
-
Brandon, Florida, Forenede Stater, 33511
- Rekruttering
- Brandon, Florida
-
Miami, Florida, Forenede Stater, 33155
- Rekruttering
- Miami, Florida
-
Miami, Florida, Forenede Stater, 33176
- Rekruttering
- Miami, Florida
-
Miami, Florida, Forenede Stater, 33166
- Rekruttering
- Miami, Florida
-
Miami, Florida, Forenede Stater, 33186
- Rekruttering
- Miami, Florida
-
Miami Lakes, Florida, Forenede Stater, 33014
- Rekruttering
- Miami Lakes, Florida
-
Orlando, Florida, Forenede Stater, 32807
- Rekruttering
- Orlando, Florida
-
St. Petersburg, Florida, Forenede Stater, 33707
- Rekruttering
- St. Petersburg, Florida
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30328
- Rekruttering
- Atlanta, Georgia
-
Rincon, Georgia, Forenede Stater, 31326
- Rekruttering
- Rincon, Georgia
-
Stockbridge, Georgia, Forenede Stater, 30281
- Rekruttering
- Stockbridge, Georgia
-
-
Michigan
-
Lansing, Michigan, Forenede Stater, 48911
- Rekruttering
- Lansing, Michigan
-
-
Mississippi
-
Flowood, Mississippi, Forenede Stater, 39232
- Rekruttering
- Flowood Mississippi
-
-
North Carolina
-
Denver, North Carolina, Forenede Stater, 28037
- Rekruttering
- Denver, North Carolina
-
Huntersville, North Carolina, Forenede Stater, 28078
- Rekruttering
- Huntersville, North Carolina
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45245
- Rekruttering
- Cincinnati, Ohio
-
Dublin, Ohio, Forenede Stater, 43017
- Rekruttering
- Dublin, Ohio
-
-
South Carolina
-
Columbia, South Carolina, Forenede Stater, 29201
- Rekruttering
- Columbia, South Carolina
-
-
Texas
-
Austin, Texas, Forenede Stater, 78731
- Rekruttering
- Austin, Texas
-
Dallas, Texas, Forenede Stater, 75251
- Rekruttering
- Dallas, Texas
-
Frisco, Texas, Forenede Stater, 75033
- Rekruttering
- Frisco, Texas
-
Houston, Texas, Forenede Stater, 77070
- Rekruttering
- Houston, Texas
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- San Antonio, Texas
-
Sugar Land, Texas, Forenede Stater, 77478
- Rekruttering
- Sugar Land, Texas
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- 18-70 years of age
- Body Mass Index (BMI) within the range ≥ 17.0 and ≤ 45 kg/m^2 (inclusive)
- Meets the diagnostic criteria of Narcolepsy Type 1 (NT1) or Type 2 (NT2) according to International Classification of Sleep Disorders, 3rd edition, Text Revision edition (ICSD-3-TR) criteria
- Is willing and able to discontinue all medications used for the treatment of narcolepsy
- Is willing and able to adhere to additional protocol requirements
Key Exclusion Criteria:
- Medical disorder other than NT1 or NT2, that is associated with excessive daytime sleepiness (EDS)
- Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological or psychiatric disease
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Group A - Narcolepsy Type 1 (Dose 1)
|
Oral cleminorexton capsule |
|
Eksperimentel: Group A - Narcolepsy Type 1 (Dose 2)
|
Oral cleminorexton capsule |
|
Placebo komparator: Group A - Narcolepsy Type 1 (placebo)
|
matching placebo capsule |
|
Eksperimentel: Group B - Narcolepsy Type 2 (Dose 1)
|
Oral cleminorexton capsule |
|
Eksperimentel: Group B - Narcolepsy Type 2 (Dose 2)
|
Oral cleminorexton capsule |
|
Placebo komparator: Group B - Narcolepsy Type 2 (placebo)
|
matching placebo capsule |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change from baseline in mean sleep latency (average of the first 4 trials) on the Maintenance of Wakefulness Test (MWT)
Tidsramme: Baseline to week 12
|
Baseline to week 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in Epworth Sleepiness Scale (ESS) total score
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Incidence, Severity, and casual relationship of participants with Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with abnormal changes from baseline in clinical laboratory tests
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with abnormal changes from baseline in vital signs
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with abnormal changes from baseline in 12-lead electrocardiograms (ECGs)
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with at least 1 endorsement of Item 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Cmax: Maximum observed plasma concentration
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Tmax: Time of Maximum Concentration for cleminorexton
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
AUC: Area under the plasma concentration-time curve
Tidsramme: Baseline to Week 12
|
Baseline to Week 12
|
|
|
Weekly Cataplexy Rate (WCR)
Tidsramme: Week 12
|
Measurement specific to Group A |
Week 12
|
|
Change from baseline in Narcolepsy Severity Scale for Clinical Trials (NSS-CT)
Tidsramme: Baseline to Week 12
|
Measurement specific to Group A |
Baseline to Week 12
|
|
Change from baseline in Narcolepsy Severity Scale-2 for Clinical Trials (NSS2-CT) total score
Tidsramme: Baseline to Week 12
|
Measurement specific to Group B |
Baseline to Week 12
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- SAFIR
- Sygdomme i nervesystemet
- Søvn
- Søvnforstyrrelse
- Søvnighed
- Psykiske lidelser
- Orexin
- Lidelser af overdreven somnolens
- Narkolepsi
- Overdreven søvnighed i dagtimerne
- Katapleksi
- Dyssomnier
- Søvnvågningsforstyrrelser
- Hypersomni
- Narkolepsi type 1
- Narkolepsi type 2
- NT2
- NT1
- Orexinreceptor 2 agonist
- Hypersomnolence
- Central Disorders of Hypersomnia
- ORX750
- Cleminorexton
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ORX750-004
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .